COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole viruses, protein subunits and peptides, viral vectors, and nucleic acids has been developed in parallel. For all types of COVID-19...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/16/2/203 |
| _version_ | 1797296828979347456 |
|---|---|
| author | Kenneth Lundstrom |
| author_facet | Kenneth Lundstrom |
| author_sort | Kenneth Lundstrom |
| collection | DOAJ |
| description | Vaccine development against SARS-CoV-2 has been highly successful in slowing down the COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole viruses, protein subunits and peptides, viral vectors, and nucleic acids has been developed in parallel. For all types of COVID-19 vaccines, good safety and efficacy have been obtained in both preclinical animal studies and in clinical trials in humans. Moreover, emergency use authorization has been granted for the major types of COVID-19 vaccines. Although high safety has been demonstrated, rare cases of severe adverse events have been detected after global mass vaccinations. Emerging SARS-CoV-2 variants possessing enhanced infectivity have affected vaccine protection efficacy requiring re-design and re-engineering of novel COVID-19 vaccine candidates. Furthermore, insight is given into preparedness against emerging SARS-CoV-2 variants. |
| first_indexed | 2024-03-07T22:11:24Z |
| format | Article |
| id | doaj.art-c149481698ae40288265f77aea30d91a |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-07T22:11:24Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-c149481698ae40288265f77aea30d91a2024-02-23T15:37:28ZengMDPI AGViruses1999-49152024-01-0116220310.3390/v16020203COVID-19 Vaccines: Where Did We Stand at the End of 2023?Kenneth Lundstrom0Pan Therapeutics, 1095 Lutry, SwitzerlandVaccine development against SARS-CoV-2 has been highly successful in slowing down the COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole viruses, protein subunits and peptides, viral vectors, and nucleic acids has been developed in parallel. For all types of COVID-19 vaccines, good safety and efficacy have been obtained in both preclinical animal studies and in clinical trials in humans. Moreover, emergency use authorization has been granted for the major types of COVID-19 vaccines. Although high safety has been demonstrated, rare cases of severe adverse events have been detected after global mass vaccinations. Emerging SARS-CoV-2 variants possessing enhanced infectivity have affected vaccine protection efficacy requiring re-design and re-engineering of novel COVID-19 vaccine candidates. Furthermore, insight is given into preparedness against emerging SARS-CoV-2 variants.https://www.mdpi.com/1999-4915/16/2/203inactivated and live whole-virus vaccinesprotein and peptide vaccinesviral vector vaccinesDNA vaccinesRNA vaccines |
| spellingShingle | Kenneth Lundstrom COVID-19 Vaccines: Where Did We Stand at the End of 2023? Viruses inactivated and live whole-virus vaccines protein and peptide vaccines viral vector vaccines DNA vaccines RNA vaccines |
| title | COVID-19 Vaccines: Where Did We Stand at the End of 2023? |
| title_full | COVID-19 Vaccines: Where Did We Stand at the End of 2023? |
| title_fullStr | COVID-19 Vaccines: Where Did We Stand at the End of 2023? |
| title_full_unstemmed | COVID-19 Vaccines: Where Did We Stand at the End of 2023? |
| title_short | COVID-19 Vaccines: Where Did We Stand at the End of 2023? |
| title_sort | covid 19 vaccines where did we stand at the end of 2023 |
| topic | inactivated and live whole-virus vaccines protein and peptide vaccines viral vector vaccines DNA vaccines RNA vaccines |
| url | https://www.mdpi.com/1999-4915/16/2/203 |
| work_keys_str_mv | AT kennethlundstrom covid19vaccineswheredidwestandattheendof2023 |